Celltrion said it will begin developing its insulin pen biosimilar with medical device manufacturer Poonglim Pharmatech, aiming to launch the product in 2025, reported The Investor.
The firms intend to develop a pen-type injector that can hold up to 80 units per injection.
The Korea Evaluation Institute of Industrial Technology selected Celltrion’s insulin pipeline as a state-designated project.
The four-year development will require a budget of 4 billion won, of which 3 billion won will be backed by government funding.
To read more NewsPoints articles, click here.